

The genomic application that streamlines the analysis of complex mutational landscape associated with major hereditary cancer disorders by combining a capture-based target enrichment kit with the analytical performance* and advanced features of the SOPHiA DDM™ platform.

Main Features

SOPHiA Hereditary Cancer Solution covers the coding regions and splicing junctions of 26 genes (target region of 105 kb) associated with Hereditary Breast and Ovarian Cancer (HBOC), Lynch and various intestinal polyposis syndromes. Probe design is optimized to guarantee high on-target rate and coverage uniformity even in GC-rich regions, including the first exon.

Gene Panel	Variants Called	Recommendations	Wet Lab
<i>ABRAXAS1, APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL1, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53, XRCC2</i>	SNVs Indels CNVs <i>Alu</i> insertions <i>PMS2</i> vs <i>PMS2CL</i> variants ² Boland inversion	Starting material 200 ng DNA Sample type Blood Samples per run for >250x coverage depth / Sequencer (Flow Cell / Ion Chip Kit)³ 48 for Illumina MiSeq® v3 (2x300bp) Up to 96 ¹ for Illumina NextSeq® 500/550 Mid Output Kit (2x150bp) Up to 48 for Ion Torrent™ Ion S5™ System using Ion 540™	Day 1: Library Preparation Day 2: Capture and Sequencing Total library preparation time: 1.5 days
		¹ Maximum number of indices available.	

Analytical Performance*

The SOPHiA DDM™ platform analyzes complex NGS data by detecting, annotating and pre-classifying multiple types of genomic variants in one unique experiment.

Analysis time from FASTQ: from 4 hours⁴

	Observed (%)	Lower 95% CI
Sensitivity	100	99.20
CNV Sensitivity	99.28	
Specificity	100	99.99
Accuracy	100	99.99
Precision	99.86	96.42
Repeatability	99.98	99.98
Reproducibility	99.93	99.93
Average on-target rate	79.39	
Coverage uniformity	99.72	
Average % of target region with depth >200x	99.95	

Performance values have been calculated based on SNVs and Indels in 159 samples processed on Illumina MiSeq®. CNV sensitivity was calculated on a total of 321 samples with 139 confirmed CNVs processed on Illumina MiSeq®.

One Simple Intuitive Platform: Beyond Analytics

Accelerated assessment and reporting of genomic variants

Dedicated features in SOPHiA DDM™ reduce the complexity of determining the significance of genomic variants and facilitate the interpretation process, thus reducing turnaround time:

- **Dual-Variant Pre-classification** – Improve assessment of variants pathogenicity with both ACMG scores and SOPHiA GENETICS' machine learning –based predictions
- **Virtual Panel** - Restrict the interpretation to sub-panels of genes of interest using the HPO or OMIM browser
- **Cascading Filters** - Apply custom filtering options for quicker screening of relevant variants and save strategies for future analyses

The platform can also provide access to Alamut Visual Plus, a full-genome browser that integrates numerous curated genomic and literature databases, guidelines, missense and slicing predictors, thus enabling a deeper variant exploration.

After the interpretation, you can generate a customizable variant report, including valuable information to support decision making.

Global support at every step

We offer local support anywhere in the world. Our dedicated bioinformaticians help save time and resources, ensuring fast resolution of workflow disruptions. In addition, our Set Up Program provides assistance with assay set up for fast and worry-free transition to routine testing.

Secure and unlimited data storage

The SOPHiA DDM™ platform provides unlimited and unrestricted storage, while keeping data safe by applying the highest industrial standards of encryption in compliance with local data security policies.

Access to the SOPHiA GENETICS community

Through the SOPHiA DDM™ platform genomics experts from hundreds of healthcare institutions interpret their findings and flag the pathogenicity level of variants. This highly valuable information enriches the variant knowledge base and is safely shared among the members of the community, supporting their decision-making process for research purposes.

1. The pseudogene *PMS2CL* is part of the analysis but not a gene responsible for disease.
 2. Due to high gene conversion rates, a definite location in *PMS2* or *PMS2CL* cannot be assigned in homologous regions of *PMS2* exons 12-15.
 3. Sequencing recommendations and specifications for other sequencing kits and instruments available upon request. Delivery time may vary according to the selected sequencing platform.
 4. Analysis time may vary depending on the number of samples multiplexed and server load.

***For Research Use Only. Not for Use in Diagnostic Procedures.**

All third party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS' use of third party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third party trademarks is to identify the corresponding third party goods and/or services and shall be considered nominative fair use under the trademark law.